71083-61-9

Usage

Uses

Used in Pharmaceutical Development:
6-chloro-4-oxo-1H-quinoline-3-carbonitrile is employed as a key intermediate in the synthesis of various drug molecules and biologically active compounds. Its unique structure allows for the development of new pharmaceuticals with diverse therapeutic applications.
Used in Organic Synthesis:
As a building block in organic synthesis, 6-chloro-4-oxo-1H-quinoline-3-carbonitrile is used to create a wide range of chemical compounds with different properties and applications.
Used in Antimicrobial Applications:
6-chloro-4-oxo-1H-quinoline-3-carbonitrile has been studied for its antimicrobial properties, making it a potential candidate for the development of new antibiotics to combat resistant bacteria.
Used in Anti-inflammatory Applications:
6-chloro-4-oxo-1H-quinoline-3-carbonitrile has also demonstrated anti-inflammatory potential, suggesting its use in the development of anti-inflammatory drugs to treat various inflammatory conditions.
Used in Anticancer Applications:
6-chloro-4-oxo-1H-quinoline-3-carbonitrile has shown promise in anticancer research, indicating its potential use in the development of novel anticancer agents targeting various types of cancer.
Used in Precursor Synthesis:
6-chloro-4-oxo-1H-quinoline-3-carbonitrile serves as a precursor for the synthesis of other biologically active compounds, contributing to the discovery and development of new therapeutic agents.

Upstream product

• 106-47-8 4-chloro-aniline 
• 19141-18-5 (Z)-3-p-Chloranilino-2-cyanacrylsaeureethylester 
• 50-00-0 formaldehyd 
• 1257230-31-1 3-(2-bromo-5-chlorophenyl)-3-oxopropanenitrile 

Relevant academic research and scientific papers

Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking

Imatinib (IMT) is the first-in-class BCR-ABL commercial tyrosine kinase inhibitor (TKI). However, the resistance and toxicity associated with the use of IMT highlight the importance of the search for new TKIs. In this context, heterocyclic systems, such as quinoline, which is present as a pharmacophore in the structure of the TKI inhibitor bosutinib (BST), have been widely applied. Thus, this work aimed to obtain new hybrids of imatinib containing quinoline moieties and evaluate them against K562 cells. The compounds were synthesized with a high purity degree. Among the produced molecules, the inhibitor 4-methyl-N3-(4-(pyridin-3-yl)pyrimidin-2-yl)-N1-(quinolin-4-yl)benzene-1,3-diamine (2g) showed a suitable reduction in cell viability, with a CC50 value of 0.9 μM (IMT, CC50 = 0.08 μM). Molecular docking results suggest that the interaction between the most active inhibitor 2g and the BCR-ABL1 enzyme occurs at the bosutinib binding site through a competitive inhibition mechanism. Despite being less potent and selective than IMT, 2g is a suitable prototype for use in the search for new drugs against chronic myeloid leukemia (CML), especially in patients with acquired resistance to IMT.

Copper-Catalyzed Synthesis of Substituted 4-Quinolones using Water as a Benign Reaction Media: Application for the Construction of Oxolinic Acid and BQCA

A copper-catalyzed three-component synthetic method has been developed for the synthesis of substituted 4-quinolone derivatives from substituted 3-(2-halophenyl)-3-oxopropane, aldehydes and aq. NH3 using water as an environmentally benign reaction media. Moreover, the synthetic utility of the obtained products has been successfully applied for the synthesis of available oxolinic acid and BQCA drugs. The key features of this approach include commercially available starting materials, broad scope, and moderate to good reaction yields. Reaction with formaldehyde, and other functionalities such as ?CN, ?NO2, ?SO2Ar, and ?COAr were also successful. In addition, reaction with heterocyclic compounds such as 3-(3-bromothiophen-2-yl)-3-oxopropanenitrile proceeded smoothly to afford tetrahydrothieno[3,2-b]pyridine-6-carbonitrile analogues. The practicality of the designed protocol was confirmed by gram scale synthesis of two derivatives. (Figure presented.).